BSGM BioSig Technologies, Inc. Stock Quote

publish chart | save to portfolio | create alert

BSGM [NASD]

BioSig Technologies, Inc.

Healthcare | Medical Devices | USA

statements

Index	-	P/E	-	EPS (ttm)	-2.23	Insider Own	6.30%	Shs Outstand	29.75M	Perf Week	13.87%
Market Cap	137.62M	Forward P/E	-	EPS next Y	-0.94	Insider Trans	3.59%	Shs Float	23.60M	Perf Month	36.07%
Income	-56.70M	PEG	-	EPS next Q	-0.39	Inst Own	18.50%	Short Float	11.71%	Perf Quarter	-38.05%
Sales	-	P/S	-	EPS this Y	-12.00%	Inst Trans	-3.47%	Short Ratio	4.52	Perf Half Y	-55.73%
Book/sh	0.96	P/B	4.83	EPS next Y	56.70%	ROA	-212.40%	Target Price	-	Perf Year	-31.36%
Cash/sh	1.10	P/C	4.21	EPS next 5Y	-	ROE	-257.40%	52W Range	2.36 - 12.43	Perf YTD	-21.62%
Dividend	-	P/FCF	-	EPS past 5Y	6.20%	ROI	-	52W High	-62.67%	Beta	1.86
Dividend %	-	Quick Ratio	6.70	Sales past 5Y	-	Gross Margin	-	52W Low	96.61%	ATR	0.39
Employees	33	Current Ratio	6.80	Sales Q/Q	-	Oper. Margin	-	RSI (14)	62.52	Volatility	8.59% 9.29%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-53.40%	Profit Margin	-	Rel Volume	0.40	Prev Close	4.55
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 18 AMC	Payout	-	Avg Volume	610.65K	Price	4.64
Recom	2.00	SMA20	25.06%	SMA50	-0.49%	SMA200	-29.69%	Volume	246,096	Change	1.98%

Mar-30-20

Initiated

ROTH Capital

Buy

Nov-19-20 11:32AM	Insider Buys BioSig Technologies Shares Benzinga +5.03%
Nov-12-20 02:11PM	BioSig to Host Business Update Conference Call on November 18, 2020 GlobeNewswire
05:56AM	Is BioSig Technologies (NASDAQ:BSGM) In A Good Position To Invest In Growth? Simply Wall St.
Oct-29-20 02:05PM	BioSig Announces Completion of PURE EP System Installation at New Medical Center GlobeNewswire
Oct-28-20 10:00AM	BioSig Issues October 2020 Shareholder Update Letter GlobeNewswire +12.54%
Oct-26-20 11:04AM	Biosig stock plunges to lead Nasdaq losers after trial of COVID-19 treatment halted MarketWatch -39.64%
07:30AM	ViralClear halts its Phase 2 Hospitalized COVID-19 Trial GlobeNewswire
Sep-30-20 09:27AM	SORRENTO THERAPEUTICS AND VIRALCLEAR ENTER INTO AGREEMENT TO EXPLORE THE COMBINATION OF ANTIBODY AND ANTIVIRAL ASSETS AGAINST COVID-19 GlobeNewswire
Sep-22-20 10:55AM	ViralClear Expands Ongoing Phase 2 Trial Size for its Oral Anti-Viral for the Treatment of COVID-19, Expands Trial Locations and Appoints Contract Manufacturing Organization to Manufacture Phase 3 Supplies of Merimepodib Oral Solution GlobeNewswire -33.66%
Sep-21-20 11:01AM	Reminder: ViralClear to Host Conference Call and Webcast on September 22, 2020 to Discuss Phase 2 Human Trial of AntiViral Merimepodib Oral Solution for Treatment of COVID-19 GlobeNewswire -5.35%
Sep-15-20 10:00AM	BioSig Releases PURE EP Study Abstract with Data Presented at European Society of Cardiologys ESC Congress 2020 GlobeNewswire +7.29%
Sep-14-20 03:00PM	BioSig Announces Abstract Acceptance to Computing in Cardiology 2020 GlobeNewswire
10:29AM	Reminder: BioSig to Host Conference Call and Webcast on September 15, 2020 to Discuss Unblinding of PURE EP Human Data GlobeNewswire
Sep-09-20 12:15PM	ViralClear to Host Conference Call on September 22, 2020, to Discuss Phase 2 Human Trial of AntiViral Merimepodib Oral Solution for Treatment of COVID-19 GlobeNewswire -9.67%
Sep-02-20 10:15AM	BioSig to Host Conference Call on September 15, 2020 to Discuss Unblinding of PURE EP Human Data GlobeNewswire +8.78%
Aug-31-20 05:00PM	LD Micro 360 Companies Set to Present this Week ACCESSWIRE
Aug-25-20 10:45AM	BioSig Technologies to Present at The LD 500 Virtual Conference ACCESSWIRE
08:30AM	BioSig Technologies to Present at The LD 500 Virtual Conference GlobeNewswire
Aug-17-20 12:16PM	Could The BioSig Technologies, Inc. (NASDAQ:BSGM) Ownership Structure Tell Us Something Useful? Simply Wall St.
Aug-06-20 10:00AM	Infectious Diseases Expert Prof. Angus Dalgleish Joins ViralClears Scientific Advisory Board GlobeNewswire
Aug-05-20 02:09PM	ViralClear Appoints Dr. Michael Sofia to Its Scientific Advisory Board GlobeNewswire
11:15AM	LD Micro - Announces Preliminary List of Presenters for the LD-500. ACCESSWIRE
Aug-04-20 09:25AM	BioSig Installs PURE EP(tm) System at Massachusetts General Hospital GlobeNewswire -9.67%
Aug-03-20 02:00PM	BioSig Awarded CAGE Code by the Systems for Award Management (SAM) GlobeNewswire
Jul-30-20 01:00PM	BioSig Technologies to Present at the Proactive Investors One2One Virtual Event on August 4, 2020 GlobeNewswire +9.43%
Jul-23-20 08:30AM	BioSig Technologies to Participate in LD Micros Zooming with LD GlobeNewswire
Jul-20-20 01:50PM	ViralClear Announces Formation of Its Scientific Advisory Board GlobeNewswire
Jul-17-20 02:42PM	BioSig Technologies to Participate in the B Riley FBR Virtual Infectious Disease Summit GlobeNewswire
Jul-16-20 05:30PM	BioSig Technologies, Inc. Adopts Stockholder Rights Agreement GlobeNewswire +5.86%
11:00AM	'Zooming with LD' to Feature 10 Distinct Companies July 20th-31st ACCESSWIRE
10:30AM	BioSig Technologies, Inc. Adopts Stockholder Rights Agreement GlobeNewswire
Jul-13-20 01:42PM	Phase II Human Trial of ViralClear's Anti-Viral for SARS-CoV-2 Coronavirus Underway at 4 Key Trial Sites GlobeNewswire
Jul-10-20 01:15PM	BioSig Submits Application to Systems for Award Management (SAM) with U.S. Government GlobeNewswire
Jul-01-20 09:15AM	BioSig Technologies Inc. Appoints Tony Zook to the Board of Directors GlobeNewswire
Jun-29-20 08:18AM	BioSig Technologies, Inc Closes $17.5 Million Common Stock Offering GlobeNewswire +9.06%
Jun-24-20 09:20AM	BioSig Technologies, Inc. Announces $17.5 Million Common Stock Only Registered Direct Offering GlobeNewswire -21.94%
Jun-22-20 02:30PM	ViralClear Partners with Catalent on Potential Treatment for COVID-19 GlobeNewswire
Jun-17-20 07:55AM	ViralClear Opens Enrollment with First Patient Dosing in Phase II Human Trial of Anti-Viral MMPD Oral Solution for Treatment of COVID-19 GlobeNewswire +5.29%
Jun-08-20 03:02PM	Reminder - BioSig Subsidiary, ViralClear to Host Conference Call on June 9th to Discuss Upcoming and Recent Developments for Phase II Human Clinical Trials of its Broad-Spectrum Oral Anti-Viral Candidate for Treatment of COVID-19 GlobeNewswire +12.02%
Jun-05-20 09:10AM	ViralClear adds St. David's HealthCare in Austin, Texas, to its Planned Phase II trial for its Broad-Spectrum Oral Anti-Viral Candidate for COVID-19 GlobeNewswire
Jun-04-20 09:25AM	BioSig Technologiess PURE EP System to be Presented in Heart Rhythm Society 2020 Science Sessions GlobeNewswire
Jun-03-20 11:45AM	BioSig Technologies Expands Intellectual Property Portfolio GlobeNewswire +7.59%
Jun-01-20 10:42AM	ViralClear to Host Conference Call on June 9th to Discuss Upcoming and Recent Developments for Phase II Human Clinical Trials of its Broad-Spectrum Oral Anti-viral Candidate for Treatment of COVID-19 GlobeNewswire +11.73%
May-28-20 08:40AM	Michael R. Dougherty Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc. GlobeNewswire -5.09%
May-20-20 10:12AM	ViralClear Closes $10.8 Million Equity Financing for Development of COVID-19 Broad-Spectrum Oral Anti-Viral Candidate Merimepodib GlobeNewswire
May-18-20 08:32AM	FDA Clears the Investigational New Drug Application to Enable the Phase II Trial of ViralClears Merimepodib, Oral Solution to Treat Adult Patients with Advanced COVID-19, to Proceed GlobeNewswire
May-14-20 08:15AM	ViralClear Publishes in F1000 Research In Vitro Data Demonstrating Synergy between Merimepodib and Remdesivir Against SARS-CoV-2, the Cause of COVID-19 GlobeNewswire
May-07-20 03:17PM	Michael Schmertzler Joins the Board of ViralClear Pharmaceuticals, a Majority-Owned Subsidiary of BioSig Technologies, Inc. GlobeNewswire
May-05-20 02:10PM	Biotech and Investment Veteran Dennis Purcell Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc. GlobeNewswire +6.35%
07:02AM	Could This Under-the-Radar Biotech Piggyback on Gilead's Remdesivir Success? Motley Fool
May-01-20 10:39AM	BioSig Resumes Clinical Activities with PURE EP System GlobeNewswire
Apr-30-20 09:20AM	ViralClear Submits In Vitro Data on Merimepodib and Remdesivir Synergistic Activity Against the COVID-19 Novel Coronavirus to a Peer-Reviewed Journal GlobeNewswire -13.30%
Apr-24-20 02:30PM	BioSig to Host Conference Call on Recent Developments of Subsidiary ViralClear and its Broad-Spectrum Oral Anti-Viral Candidate Merimepodib for the Treatment of COVID-19 GlobeNewswire +12.84%
09:25AM	BioSig Subsidiary ViralClear Submits Investigational New Drug Application to the FDA for Phase II Clinical Trials for Merimepodib, an Orally Administered Treatment for Patients with COVID-19 GlobeNewswire
Apr-23-20 09:15AM	ViralClear Publishes Comparative In Vitro Data on Merimepodib and Remdesivir Activity Against the COVID-19 Novel Coronavirus in F1000 Research GlobeNewswire +7.08%
Apr-21-20 02:36PM	Tony Zook Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc. GlobeNewswire
10:15AM	BioSig Subsidiary ViralClear Submits Application for Vicromax Through FDAs Coronavirus Treatment Acceleration Program (CTAP) to Seek Acceleration of its Planned Clinical Trials GlobeNewswire
Apr-17-20 02:07PM	BioSig Issues April 2020 Shareholder Update Letter GlobeNewswire +12.72%
01:27PM	New startup with local ties testing compound with Mayo Clinic to starve COVID-19 American City Business Journals
Apr-16-20 09:45AM	Mayo Clinic preparing to Commence Phase II FDA clinical trial for the treatment of COVID-19 with Vicromax GlobeNewswire
Apr-09-20 08:22AM	Positive Data Generated by Biosig Subsidiary ViralClear on Covid-19 Coronavirus Published in bioRxiv GlobeNewswire +10.94%
Apr-03-20 01:10PM	BioSig to Host Telebriefing on Development Updates Regarding Vicromax(tm), a Novel Broad-Spectrum Anti-Viral Candidate That May Treat COVID-19 GlobeNewswire +42.38%
Mar-31-20 08:45AM	Jerome Zeldis, M.D., Ph.D, Appointed as Executive Chair of ViralClear Pharmaceuticals, Inc. GlobeNewswire -17.03%
Mar-25-20 07:52AM	BioSig subsidiary NeuroClear acquires license for a broad-spectrum anti-viral agent that may treat COVID-19. Laboratory results demonstrate high level of activity against COVID-19 in cell culture GlobeNewswire
Mar-22-20 08:31AM	Who Has Been Buying BioSig Technologies, Inc. (NASDAQ:BSGM) Shares? Simply Wall St.
Mar-10-20 08:05AM	Florida Cardiologist Zachariah P. Zachariah, M.D. Joins BioSig Technologies, Inc. Advisory Board GlobeNewswire
Mar-04-20 07:52AM	BioSig Appoints John W. Osborn, Ph.D. as Consultant on Autonomic Neuromodulation GlobeNewswire
Mar-03-20 12:20PM	BioSig to Webcast its Presentation at the Cowen and Companys 40th Annual Health Care Conference GlobeNewswire
Feb-26-20 08:33AM	BioSig to Present at the Cowen & Co. 40th Annual Health Care GlobeNewswire
Feb-25-20 03:25PM	BioSig Announces Closing of Public Offering of Common Stock GlobeNewswire
Feb-21-20 08:45AM	BioSig Announces $10 Million Public Offering of Common Stock GlobeNewswire -10.22%
07:46AM	The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion Benzinga
Feb-20-20 04:18PM	BioSig Announces Proposed Public Offering of Common Stock GlobeNewswire -6.25%
Feb-19-20 08:33AM	BioSig Completes 100th Patient Case with PURE EP(TM) System GlobeNewswire +13.74%
Jan-21-20 07:52AM	BioSig to Present at the 25th Annual International AF Symposium GlobeNewswire
Jan-16-20 07:52AM	BioSig to Commence Patient Cases at Mayo Clinic GlobeNewswire
Jan-14-20 07:52AM	BioSig Awarded Additional US Patent Claims for its PURE EP(TM) System GlobeNewswire
Dec-23-19 05:57AM	BioSig Technologies, Inc. (NASDAQ:BSGM): What Does Its Beta Value Mean For Your Portfolio? Simply Wall St.
Dec-03-19 07:52AM	BioSig Technologies Announces New Collaboration on Development of Artificial Intelligence Solutions in Healthcare GlobeNewswire
Dec-02-19 03:40PM	BioSig Technologies Partners Mayo Clinic to Treat Arrhythmia Zacks
Nov-26-19 07:52AM	BioSig Technologies Signs Three New Licensing Agreements with Mayo Clinic GlobeNewswire
Nov-21-19 07:52AM	BioSig Commences Clinical Trial Enrollment for PURE EP System GlobeNewswire
Nov-18-19 07:52AM	BioSig Technologies Welcomes the Creation of New Bioelectronic Medicine Alliance GlobeNewswire
Nov-14-19 07:52AM	BioSig Technologies Issues November 2019 Shareholder Letter GlobeNewswire
Nov-07-19 07:52AM	BioSig Technologies Invests in Union Colleges Internship Program GlobeNewswire
Nov-06-19 07:52AM	Sasha Gentling, CFA Joins BioSig as Director of Business Development GlobeNewswire +8.14%
Oct-29-19 07:52AM	BioSig Appoints Andrew Ballou as Vice President of Investor Relations GlobeNewswire
Oct-24-19 11:02AM	Here's Why We're Watching BioSig Technologies's (NASDAQ:BSGM) Cash Burn Situation Simply Wall St.
Oct-15-19 07:52AM	BioSig Opens a Technology Development Office in Rochester, MN GlobeNewswire
Oct-10-19 07:52AM	BioSig to Participate at The 14th Annual International Symposium on Ventricular Arrhythmias: Pathophysiology & Therapy GlobeNewswire
Sep-30-19 07:52AM	BioSig to Present Clinical Observations at Venice Arrhythmias 2019 GlobeNewswire
Sep-26-19 07:52AM	Global Marketing and Strategy Leader Martha Pease Joins BioSig Board of Directors GlobeNewswire
Sep-16-19 08:09AM	BioSig Technologies-Mayo Clinic Ink Electrophysiology Deal Zacks
Sep-12-19 07:52AM	BioSig Technologies Signs a New Licensing Agreement with Mayo Clinic GlobeNewswire
Sep-09-19 01:06PM	BioSig Technologies, Inc. (NASDAQ:BSGM) Insiders Increased Their Holdings Simply Wall St.
Sep-05-19 07:52AM	BioSigs Subsidiary NeuroClear Technologies, Inc. Raises $3.7 million GlobeNewswire
Aug-01-19 09:00AM	BioSig Allowed Additional Foundational US Patent for its PURE EP(tm) System GlobeNewswire
Jul-24-19 07:52AM	Julie Stephenson Joins BioSig as Senior Director of Clinical Affairs GlobeNewswire
Jul-18-19 07:52AM	Olivier Chaudoir Joins BioSig as Director of Marketing GlobeNewswire
Jul-15-19 10:45AM	BioSig Technologies, Inc. to Receive 15 Units of PURE EP System from Manufacturer for Commercial Installation - Corrected Version GlobeNewswire

BioSig Technologies, Inc., a medical device company, engages in developing and commercializing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. The company's proprietary product include precise uninterrupted real-time evaluation of electrograms electrophysiology system, a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology procedures in an electrophysiology laboratory under the supervision of licensed healthcare practitioners who are responsible for interpreting the data. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation and ventricular tachycardia. BioSig Technologies, Inc. was founded in 2009 and is headquartered in Westport, Connecticut.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LONDONER KENNETH L	Chief Executive Officer	Nov 24	Buy	4.33	1,000	4,330	1,343,558	Nov 25 09:45 AM
LONDONER KENNETH L	Chief Executive Officer	Nov 23	Buy	4.41	3,000	13,230	1,342,558	Nov 25 09:45 AM
LONDONER KENNETH L	Chief Executive Officer	Nov 18	Buy	3.95	4,500	17,755	1,339,558	Nov 19 09:45 AM
LONDONER KENNETH L	Chief Executive Officer	Nov 17	Buy	3.89	4,000	15,545	1,335,058	Nov 19 09:45 AM
LONDONER KENNETH L	Chief Executive Officer	Nov 16	Buy	3.98	5,000	19,900	1,331,058	Nov 17 09:46 AM
LONDONER KENNETH L	Chief Executive Officer	Nov 13	Buy	3.90	2,000	7,800	1,326,058	Nov 16 09:48 AM
LONDONER KENNETH L	Chief Executive Officer	Nov 12	Buy	3.66	5,000	18,300	1,324,058	Nov 13 09:45 AM
LONDONER KENNETH L	Chief Executive Officer	Nov 10	Buy	3.45	7,200	24,807	1,319,058	Nov 12 09:47 AM
LONDONER KENNETH L	Chief Executive Officer	Nov 09	Buy	3.42	16,600	56,816	1,311,858	Nov 10 09:45 AM
LONDONER KENNETH L	Chief Executive Officer	Nov 06	Buy	3.34	12,500	41,765	1,295,258	Nov 09 10:00 AM
LONDONER KENNETH L	Chief Executive Officer	May 29	Buy	9.26	4,000	37,020	1,282,758	May 29 11:30 AM
ZELDIS JEROME B	Director	May 28	Buy	10.49	1,000	10,489	107,944	May 28 10:58 AM
LONDONER KENNETH L	Chief Executive Officer	May 26	Buy	10.84	3,600	39,014	1,278,758	May 26 10:57 AM
Pease Martha	Director	Mar 23	Buy	3.00	3,000	9,000	9,437	Mar 25 02:55 PM
CHAUSSY STEVE	Chief Financial Officer	Mar 19	Buy	3.05	1,866	5,697	679,128	Mar 19 02:30 PM
Kowalski John M	VP of Sales	Mar 19	Buy	2.98	3,000	8,940	112,000	Mar 19 02:16 PM
Kowalski John M	VP of Sales	Mar 17	Buy	2.71	1,000	2,710	109,000	Mar 17 12:16 PM
CHAUSSY STEVE	Chief Financial Officer	Mar 16	Buy	2.61	4,000	10,440	677,262	Mar 16 01:35 PM
LONDONER KENNETH L	Chief Executive Officer	Mar 16	Buy	2.76	8,800	24,288	1,270,791	Mar 16 11:25 AM
LONDONER KENNETH L	Chief Executive Officer	Mar 16	Buy	2.70	4,367	11,786	1,275,158	Mar 16 02:22 PM
Kowalski John M	VP of Sales	Mar 16	Buy	2.92	1,000	2,920	108,000	Mar 17 12:16 PM
LONDONER KENNETH L	Chief Executive Officer	Jan 16	Option Exercise	5.23	100,000	523,000	1,358,393	Jan 21 08:14 PM
CHAUSSY STEVE	Chief Financial Officer	Jan 16	Option Exercise	5.23	12,000	62,760	684,830	Jan 21 08:08 PM
ODONNELL JEFFREY F	Director	Dec 18	Option Exercise	5.23	38,320	200,414	257,695	Dec 20 09:56 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience